Poster apresentado na 15ª Reunião Científica da Sociedade Portuguesa de Medicina Laboratorial, Porto, 2023N/

Amorim, António

Cainé, Laura

Corte Real, F.

Fadoni, Jennifer

Mofreita, Vânia

Mukan, Olena

Nascimento, Rui

Rodrigues, Joana

English

Repositório Comum

RESULTSMATERIAL AND METHODSINTRODUCTIONHepatitis A virus (HAV) continues to be a public health issue worldwide[1]. HAV infection is caused by the hepatitis A virus and transmission occurmainly via fecal-oral route [1,2,4], by ingesting contaminated food or water(especially to travelers visiting regions with intermediate or high endemicity,such as Africa, South and Central America and Asia), by direct contact with aninfected person or using intravenous drugs [1-4]. However, this infection canbe prevented through vaccination [1,3,5].The level of endemicity of this virus can be determined by the prevalenceof total antibodies directed against HAV (anti-HAVtotal) in the adult population[5]. Due to the improvement of socioeconomic and sanitary conditions andvaccination, Portugal has become a country in transition from endemicity:from high to intermediate [2,6]43Figure 1 - Schematization of the methodology used for samples analysis.HEPATITIS A: ULTRASENSITIVE ENZYME -LINKED FLUORESCENCE ASSAY IN OCCASIONAL DETECTION OF PRIOR CONTACT IN A MEDICO -LEGAL SAMPLE IN LISBON1Instituto Nacional de Medicina Legal e Ciências Forenses, Laboratório de Virologia e de Análises Clínico-Forenses, Portugal; 2Faculdade de Ciências da Universidadede Lisboa, Lisboa, Portugal; 3Faculdade de Medicina da Universidade do Porto, Porto, Portugal; 4Faculdade de Medicina da Universidade de Coimbra, Coimbra,Portugal; 5REQUIMTE – Analytical Development Group, Laboratório Associado, Portugal.Vânia Mofreita1,2, Laura Cainé1,3,5, Joana Rodrigues1,2, Rui Nascimento1,2, Olena Mukan, Jennifer Fadoni1, Francisco Côrte-Real1,4, António Amorim1,2,5The purpose of this study was to perceive theprevalence of anti-HAVtotal and the trend in the level ofendemicity in the population of the Lisbon region throughultrasensitive enzyme-linked fluorescence assay in amedico-legal sample.From 43 individuals involved in medico-legal expertise, between 2021and 2022, in the Lisbon region, carried out by the medico-legal services inthat region, blood was collected with informed consent whenever applicableand, after blood centrifugation, a VIDAS® Anti-HAV Total enzymeimmunoassay was carried out (Figure 1).The certified statistical database about Portugal, PORDATA, was used tounderstand the constitution of the Portuguese population at that time.Anti-HAVtotal laboratory results greater or equal than 15 mUL/mL wereconsidered seropositive, revealing previous infection or vaccination.REFERENCES[1] Lazcano-Ponce E., Conde-Gonzalez C., Rojas R., et al. (2013). Seroprevalence of hepatitis A virus in a cross-sectional study in Mexico. Human Vaccines and Immunotherapeutics, 9(2), 375–381.[2] Antunes H., Macedo M., Estrada A. (2004). Prevalência do vírus da hepatite A: Primeiros resultados de baixa endemicidade em Portugal. ActaMédica Portuguesa, 219–223.[3] Gomes A., Vieira C., Outeirinho C., et al. (2022). Relatório do Programa Nacional para as Hepatites Virais. Direção-Geral da Saúde, 1-71.[4] Shapiro C. N., Margolis H.S. (1993). Worldwide epidemiology of hepatitis A Virus infection. Journal of Hepatology, 1–14.[5] Guenifi W., Laouamri S., Lacheheb A. (2017). Changes in prevalence of hepatitis A and associated factors in Setif-Algeria. Revue d’Epidemiologie et de Sante Publique, 65(6), 437–442.[6] Badur S., Blystad H,. Bonanni P., et al. (2011). Viral Hepatitis Prevention Board (VHPB). WHO, 19(1), 1-40. Available inhttps://www.vhpb.org/files/html/Meetings_and_publications/Viral_Hepatitis_Newsletters/vhv19n1.pdf (accessed 12 setember 2022).[7] FFMS. (2022). População residente em Portugal em 2021. PORDATA. Available in https://www.pordata.pt/ (accessed 12 setember 2022).[8] Martins H. C., Matos R., Almeida L., et al. (2017). Inquérito Serológico Nacional 2015-2016: Doenças Evitáveis por Vacinação. Instituto Nacional de Saúde Doutor Ricardo Jorge, 1-184.[9] European Centre for Disease Prevention and Control. (2016). Hepatitis A virus in the EU/EEA, 1975–2014 a systematic review of seroprevalence and incidence comprising Europeansurveillance data and national vaccination recommendations. ECDC, 1-13415ª Reunião Científica da Sociedade Portuguesa de Medicina Laboratorial, April 14 - April 15, 2023 OBJECTIVESFemales represented 65.12%. Most were aged between 55 and 64 years(32.56%). The Portuguese population also reflected a higher incidence offemales (52.43%) but aged over 64 years (23.50%) [7].The prevalence of anti-HAVtotal was 60.47%, with emphasis on females(53.85%) and age groups aged over 54 years (46.15% and 34.61%, between 55and 64 years and over 64 years, respectively). These results are onlyindicative, therefore have no statistical significance as they result from aconvenience sample in which it was not yet possible for us to determine thepresence of IgG.DISCUSSION/CONCLUSIONSSeropositivity comprised 60.47%. The analysis of theseresults reveals that the lowest proportion of seropositivitywas concentrated in younger people, reaching higher valuesat ages over 54 years, corroborating what was described inthe National Serological Survey, as well as the fact that theseropositivity rate does not present significant differencesbetween female and male, in the different age groups [8].It can be assumed that Portugal is a country of lowendemicity, in agreement with what is considered by theEuropean Centre for Disease Prevention and Control [9].Since vaccination is not mandatory and due to the lowrate of the vaccinated population, it is presumed that mostseropositive individuals reflect previous HAV infection, mainlyin the presence of IgG.Thus, it will be interesting to study anti-HAV IgM antibodies inthat population, to understand prior exposure to the virus –as a result of infection or vaccination.

Hepatitis A: Ultrasensitive enzyme-linked fluorescence assay in occasional detection of prior contact in a medico-legal sample In Lisbon

https://comum.rcaap.pt/bitstream/10400.26/49766/1/Hepatite%20A%20Poster.pdf

Hepatitis A: Ultrasensitive enzyme-linked fluorescence assay in occasional detection of prior contact in a medico-legal sample In Lisbon

Abstract

Similar works

Full text

Available Versions

Repositório Comum